Potent

BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Jul 11, 2007 - BioSantePharmaceuticals, Inc. (Amex: BPA) today announced new positiveresults demonstrating that its calcium phosphate (CaP)nanoparticle-based vaccine adjuvant, BioVant(TM), may serve as aneffective vaccine adjuvant for the development of a dose sparingvaccine against H5N1 avian flu, widely known as bird flu. The new results are based on...

New Information on the Potential of Plasmin Shared at ISTH Congress

RESEARCH TRIANGLE PARK, N.C. & GENEVA--(BUSINESS WIRE)--Jul 11,2007 - New information representing the continuing research anddevelopment program for Plasmin (Human), TAL-05-00018, waspresented by Talecris Biotherapeutics, Inc.(http://www.talecris.com) this week at the XXIst InternationalSociety for Thrombosis and Haemostasis (ISTH) Congress in Geneva,Switzerland. The information includ...

CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa

-- New Preclinical Information May Correlate with Clinical HbA1cReductions Observed in Phase 3 CARISA and MERLIN TIMI-36 ClinicalTrials -- PALO ALTO, Calif., July 9, 2007 /PRNewswire-FirstCall/ -- CVTherapeutics, Inc. announced today that researchers have completedpreliminary preclinical studies showing that ranolazine increasedglucose stimulated insulin secretion in pancreatic beta cells...

YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy

MISSISSAUGA, ON, July 09, 2007 /PRNewswire-FirstCall/ - YMBioSciences Inc. , an oncology company that identifies, developsand commercializes differentiated products for patients worldwide,today announced that a study presented by investigators from KinkiUniversity School of Medicine and Kyoto University at the 11thmeeting of The Japanese Association for Molecular Target Therapy ofCancer...

Peer Reviewed Journal Article Indicates Repros' Proellex Exhibits Potential for New Approach to the Treatment and Prevention of Breast Cancer

THE WOODLANDS, Texas--(BUSINESS WIRE)--Jul 5, 2007 - ReprosTherapeutics Inc. (NasdaqGM:RPRX) today announced that an articlehas been published in the July 1, 2007 issue of Oncology Reportsindicating a potential for a new approach to the treatment ofbreast cancer using Proellex. The article reviews the findings froma study conducted in an accepted in vivo rat model of breastcancer. The study...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme

CAMBRIDGE, U.K. 2nd July 2007 - CeNeS Pharmaceuticals (AIM:CEN)("CeNeS" or "the Company") the Cambridge-based biopharmaceuticalcompany today announced that a paper published this week in CNSDrugs(1) further supports the hypothesis that acatechol-O-methyltransferase (COMT) inhibitor that acts in thebrain would be a useful agent to address profound cognitivedeficits in schizophrenia and bi...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal

Focus On AV411's Unique Mechanism of Action and Broad Potential forthe Treatment of Neurological Conditions ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc.(Nasdaq:AVGN), a biopharmaceutical company innovating therapeuticsfor the treatment of neurological conditions, announced today thatExpert Opinion on Investigational Drugs has published an articlefeaturing...

Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA

- ARI-2243 is an highly potent DPP-4 inhibitor, possessing Ki of 27pM BOSTON, June 25, 2007 /PRNewswire/ -- Arisaph Pharmaceuticals,Inc., a privately held drug discovery biopharmaceutical company,announced today the results of its potent, smart DPP-4 inhibitor,ARI-2243, presented at the 67th session of the American DiabetesAssociation meeting in Chicago, Illinois. The results showed that...

New Study Shows That telmisartan has Greater Renoprotective Potential Thanlosartan in Hypertensive Patients With Type 2 Diabetes

MILAN, Italy, June 15 /CNW/ - Today AMADEO, one of thefirst studies to compare the protective potential of twoangiotensin receptor blockers in hypertensive patients withdiabetic nephropathy, was presented at the European Societyof Hypertension, Milan. The results from this study show that telmisartan reduces proteinuria to a significantly greater extentthan losartan.(1)...

Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's Disease

NEW YORK--(BUSINESS WIRE)--Jun 14, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicatedto the commercialization of products for a variety of malignant,degenerative and auto-immune indications, announced today thatPluristem's PLacenta eXpanded (PLX) cells have been demonstrated invitro to have properties that the Company believes gives thesecells th...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - ElixirPharmaceuticals, Inc., announced today new preclinical dataconfirming ghrelin antagonism as a potential method for regulatingmetabolism, decreasing body weight and managing blood glucose. Thedata were presented in poster sessions during ENDO 07, TheEndocrine Society's 89th Annual Meeting, being held in Toronto,Canada. Elixir is focused...

Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas

SAN CARLOS, Calif., June 05, 2007 /PRNewswire-FirstCall/ --Nuvelo, Inc. today announced the publication of data from apreclinical study of novel monoclonal antibodies against thecell-surface protein NTB-A. The data demonstrate that NTB-A is apotential new target for immunotherapy of B-cell malignanciesincluding leukemia and lymphomas. The study, entitled "The lymphoidcell surface recepto...

Genmab's HuMax-EGFr Shows Broad Potential in Cancer Treatment

COPENHAGEN, June 3, 2007 - Genmab A/S (CSE: GEN) announcedtoday pre-clinical data illustrating its fully humanHuMax-EGFr™ (zalutumumab) antibody may have broad potentialto treat cancers that over-express several types of EGFr (epidermalgrowth factor receptor). Recently, mutations which appear to alter the signaling abilityof EGFr have been identified in tumors from lung canc...

Hemispherx Presents Potential Avian Influenza Treatment Breakthrough at Paris Conference

PARIS--(BUSINESS WIRE)--May 31, 2007 - Hemispherx Biopharma, Inc.(AMEX: HEB), a biopharmaceutical company engaged in the clinicaldevelopment and manufacture of new drug entities for pandemicdisease threats, announced today a new scientific report featuringits antiviral therapeutic product candidate Alferon-LDO incombating highly pathogenic avian influenza (HPAI), also known as"bird flu." Al...

Preclinical Study Finds Protease Inhibitor-Resistant HIV May Have Reduced Potential to Develop Resistance to Panacos' Bevirimat

WATERTOWN, Mass.--(BUSINESS WIRE)--May 29, 2007 - PanacosPharmaceuticals, Inc. (NASDAQ:PANC), a biotechnology companydedicated to developing the next generation of antiviraltherapeutic products, today announced the results of a new studyindicating that HIV resistant to Protease Inhibitors (PI) may havereduced potential for the development of resistance to the HIVmaturation inhibitor bevirim...

Positive Clinical Data on CC-10004 Confirms Potential as Novel Oral Approach to Treating Inflammatory Diseases

Celgene to Advance Clinical and Regulatory Development of OralAnti-Inflammatory Franchise SUMMIT, N.J., May 22, 2007 /PRNewswire-FirstCall/ -- CelgeneCorporation announced its plans to advance the development ofleading oral anti-inflammatory candidates across a broad range ofinflammatory diseases. CC-10004 (apremilast), an oral TNFantagonist and anti-inflammatory agent has demonstrated si...

Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Gilead Sciences,Inc. (Nasdaq:GILD) today announced results of two long-term studiesevaluating ambrisentan, an investigational endothelin receptorantagonist (ERA) for the treatment of patients with pulmonaryarterial hypertension (PAH). These long-term data are from patientswho originally participated in the two pivotal Phase III ARIESstudies and...

New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension

-FIXED DOSE COMBINATION WITH DIURETIC ACCEPTED FOR REVIEW BYFDA- BASEL, Switzerland and BRIDGEWATER, NJ, 21 May 2007 -Speedel (SWX: SPPN) today welcomed the significant new results fromclinical trials of SPP100 (aliskiren, Tekturna/Rasliez[1])presented by investigators at the 22nd Annual Scientific Meetingand Exposition of the American Society of Hypertension (ASH) inChicago, IL,...

Avant’s Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

Single-Dose Oral Ty800 Vaccine Immunogenic & Well-Toleratedin NIH-Sponsored Phase 1/2 Study NEEDHAM, MA (May 18, 2007) - AVANT Immunotherapeutics, Inc.(Nasdaq: AVAN) announced today positive preliminary results from aninvestigational double-blind, placebo-controlled Phase 1/2dose-escalating clinical trial of its typhoid fever vaccinecandidate, Ty800, in healthy volunteers. The...

Avant's Typhoid Fever Vaccine Demonstrates Excellent Clinical Potential

NEEDHAM, Mass.--(BUSINESS WIRE)--May 18, 2007 - AVANTImmunotherapeutics, Inc. (Nasdaq: AVAN) announced today positivepreliminary results from an investigational double-blind,placebo-controlled Phase 1/2 dose-escalating clinical trial of itstyphoid fever vaccine candidate, Ty800, in healthy volunteers. Theresearchers found the single-dose, oral vaccine to be welltolerated and immunogenic, wi...

Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments

Addiction can lead to hospitalization and drug withdrawal CHICAGO, May 15, 2007 /PRNewswire/ -- A new survey of hundredsof migraine patients and physicians commissioned by the NationalHeadache Foundation and conducted by Harris Interactive shows that20 percent of migraine patients are currently taking potentiallyaddictive medications that contain barbiturates or opioids and havenot been a...

Multiferon Shows Potent Activity in Preventing the Progression of Malignant Melanoma; Study to be Published

PLANTATION, Fla., May 08, 2007 /PRNewswire-FirstCall/ --Viragen, Inc. and Viragen International, Inc. today announcedresults from a sponsored in vitro study conducted at UmeaUniversity in Sweden, which found that Multiferon(R) (multi-subtype, human alpha interferon) suppressed development ofresistant human melanoma clones to a far greater degree thanrecombinant alpha interferon. The stud...

Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study ofHGS-ETR1 - ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today reported that clinical and preclinicalevidence continues to emerge demonstrating that its TRAIL receptorantibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), havesignificant potential for use in the treatment of a bro...

Prospective Model Outlined Potential Time and Cost Savings of Once-Monthly Anemia Treatment

DALLAS, Texas and NUTLEY, N.J., April 23, 2007 /PRNewswire/ --An activity-based cost analysis demonstrated that if a renal anemiatreatment administered once every four weeks replaced thrice weeklyadministration of epoetin alfa, hemodialysis centers may save anestimated 802 nursing hours and more than $44,000 per year per 100patients. These data, from a multi-center prospective analysis of...

Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets

Data Presented at Society for Biomolecular Sciences Conference THE WOODLANDS, Texas, April 18, 2007 /PRNewswire-FirstCall/ --Lexicon Genetics Incorporated announced that data was presentedtoday highlighting potential therapeutic targets related to itscollaboration with Genentech, Inc. at the Society for BiomolecularSciences 13th Annual Conference & Exhibition in Montreal,Canada. These...

Aeolus Pharmaceuticals' AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy

LAGUNA NIGUEL, Calif.--(BUSINESS WIRE)--Apr 19, 2007 - AeolusPharmaceuticals, Inc. (OTCBB:AOLS) announced the presentation ofdata by researchers at Loma Linda University Medical Center,National Jewish Medical and Research Center and Duke Universityshowing that one of the Company's metalloporphyrin antioxidants,AEOL 10113, demonstrated protection of healthy normal cells in micewith prostate...

Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention

BOTHELL, Wash., April 18, 2007 /PRNewswire-FirstCall/ -- HelixBioMedix, Inc. today announced that Timothy Falla, Ph.D, ChiefScientific Officer, will present an update on the company's newgeneration of small molecule peptide (lipohexapeptide) technologyat the BIO International Convention. The convention will take placeat the Boston Convention & Exhibition Center in Boston, MA fromMay...

Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting

BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ --ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate,may have potential as a chemopreventive agent, according toworld-renowned mesothelioma researcher Michele Carbone M.D., Ph.D.,at this week's American Association for Cancer Research (AACR)Annual Meeting. In a series of poster presentations, Dr. Carbone highlig...

Idera Pharmaceuticals Announces Presentations of Preclinical Data on New Potential Oncology Applications of its TLR9 Agonists at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - IderaPharmaceuticals, Inc. (AMEX: IDP) today announced two presentationsof data for two new potential applications in oncology of its novelagonists of Toll-like receptor 9 (TLR9) at the Annual Meeting ofthe American Association for Cancer Research (AACR) being held inLos Angeles, CA, April 14-18, 2007. The first presentation covereda preclin...

Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models

- Data presentations at American Association for Cancer Researchannual meeting - PRINCETON, N.J., April 17, 2007 /PRNewswire-FirstCall/ --Medarex, Inc. today presented preclinical data demonstrating potentanti- tumor activity from two separate studies exploring theefficacy and safety in animal models of anti-CD19 and anti-CD70antibody-drug conjugates. CD19 and CD70 are both attractive tar...

Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection

- Findings Published in Blood Highlight Millennium Leadership inPersonalized Medicine and Could Strengthen the Role of VELCADE asFoundation of Therapy in Broad Range of Multiple Myeloma Patients - CAMBRIDGE, Mass., April 17, 2007 /PRNewswire-FirstCall/ --Findings published in the April 15th issue of Blood show that ateam of researchers led by Millennium Pharmaceuticals, Inc. hasdiscovered...

Sunesis Presents Data Supporting SNS-032's Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting

Results from Non-clinical Studies Confirm Mechanism of Action andProvide Guidance for Dosing SOUTH SAN FRANCISCO, April 16, 2007 /PRNewswire-FirstCall/ --Sunesis Pharmaceuticals, Inc. presented non-clinical datademonstrating SNS-032's apoptotic activity in a multiple myelomamodel. These data were presented today in a poster session duringthe Annual Meeting of the American Association for...

Inotek Pharmaceuticals Announces Publication of Animal Data from Study of PARP Inhibition as Potential Preventative of Brain Injury Following Stroke

BEVERLY, Mass.--(BUSINESS WIRE)--Apr 10, 2007 - InotekPharmaceuticals Corporation announced today the publication in thejournal Stroke of preclinical animal data showing that theadministration of a poly(ADP-Ribose) polymerase (PARP) inhibitorhas a large protective effect on the survival of certain braincells following a stroke. PARP is a nuclear enzyme that directs therepair of damaged DNA...

Pieris Demonstrates Potent Anti-Tumor Activity of a VEGF-Specific Anticalin in Preclinical Studies

FREISING-WEIHENSTEPHAN, Germany, March 29, 2007 /PRNewswire/ --Pieris AG, a bio-pharmaceutical company developing therapeuticproducts comprising of Anticalins(R), a novel proprietary class ofhuman binding proteins, announced today it has demonstrated potentanti-tumor activity of PRS-050. The positive results with PRS-050,a VEGF-specific Anticalin(R) with extended serum half life, wereach...

In vivo Study Results Demonstrating Potential of Alfacell's Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research

BLOOMFIELD, N.J., March 26, 2007 /PRNewswire-FirstCall/ --Alfacell Corporation today announced that in vivo study resultsdemonstrating the potential of ONCONASE (ranpirnase) for thetreatment of non-small cell lung cancer (NSCLC) were recentlypublished in Anticancer Research (2007; 27: 299- 308). Based on the work of Intae Lee, Ph.D., at the University ofPennsylvania, a paper entitl...

ImmuneRegen BioSciences Announces Promising Data on Homspera Suggesting Potential as a Co-Therapeutic Agent

Compound Could Be Utilized as an Adjuvant and Play Key Role in theTreatment of Influenza and Cancer SCOTTSDALE, Ariz., March 20, 2007 /PRNewswire-FirstCall/ --ImmuneRegen BioSciences, a wholly owned subsidiary of IRBioSciences Holdings, Inc. , announced today that data obtained bythe Company on its Substance P analog, Homspera, suggests that thecompound has potential value as a co-therape...

Inflazyme Announces Outcome of Review of Phase 2b Asthma Study: Potential Mitigating Factors Identified which Prevent Clear Interpretation of Results

RICHMOND, British Columbia, March 12, 2007--InflazymePharmaceuticals Ltd. (TSX: IZP). As announced on January 29, 2007,the preliminary results of the Phase 2b CAPSICS study withIPL512,602 showed no statistical or clinical difference betweenpatients who received drug or placebo. However, the placeboresponse was surprisingly large and consistent across a number ofthe end-points, which prom...